Leo’s Law

House Bill

H.R. 7693

119th Congress

Leo’s Law

In Committee

Introduced:Feb 25, 2026

Primary Sponsor

Sponsor information unavailable

Cosponsors

0

Quick Stats

Summary

This bill aims to address how the COVID-19 pandemic affected incentives for developing orphan drugs, which are medications for rare diseases. It would adjust provisions in federal drug law to account for pandemic-related disruptions that may have impacted the orphan drug development program.

Latest Action

Referred to the House Committee on Energy and Commerce.

Introduced2/25/2026

StatusReferred to the House Committee on Energy and Commerce.

ChamberHouse

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

Leo’s Law

This bill aims to address how the COVID-19 pandemic affected incentives for developing orphan drugs, which are medications for rare diseases. It would adjust provisions in federal drug law to account for pandemic-related disruptions that may have impacted the

Community Breakdown

Pass

0%

Fail

0%

0 predictions

This bill aims to address how the COVID-19 pandemic affected incentives for developing orphan drugs, which are medications for rare diseases. It would adjust provisions in federal drug law to account for pandemic-related disruptions that may have impacted the orphan drug development program.

Bill Number: 7693
Introduced: 2/25/2026
Status: Referred to the House Committee on Energy and Commerce.

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: Leo’s Law
Bill Number: 7693
Sponsor: No sponsor
Status: Referred to the House Committee on Energy and Commerce.
Introduced: 2/25/2026
Summary: This bill aims to address how the COVID-19 pandemic affected incentives for developing orphan drugs, which are medications for rare diseases. It would adjust provisions in federal drug law to account for pandemic-related disruptions that may have impacted the orphan drug development program.

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

This bill aims to address how the COVID-19 pandemic affected incentives for developing orphan drugs, which are medications for rare diseases. It would adjust provisions in federal drug law to account for pandemic-related disruptions that may have impacted the orphan drug development program.

Last updated: 2/28/2026

Key Points

Main provisions of the bill

The bill addresses incentives under federal law that encourage pharmaceutical companies to develop orphan drugs for rare diseases.
It specifically focuses on mitigating negative effects that the COVID-19 pandemic had on the orphan drug development program.
Orphan drugs treat rare conditions affecting fewer than 200,000 people in the United States and receive special development incentives.
The bill would modify provisions in the Federal Food, Drug, and Cosmetic Act related to these development incentives.

How This Impacts Americans

Potential effects on citizens and communities

This bill would primarily affect pharmaceutical companies that develop treatments for rare diseases, as well as patients with rare conditions who depend on orphan drugs. By addressing pandemic-related disruptions to development incentives, it could help ensure continued investment in medications for rare diseases that might otherwise be unprofitable to develop.

Policy Areas

No policy areas assigned yet.

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

7693, 119th Congress (2026). "Leo’s Law". Source: Voter's Right Platform. https://votersright.org/bills/119-hr-7693

Public Opinions

Community submissions related to this bill.

Share your opinion

No public opinions yet. Be the first to submit one for this bill.